Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
23.56
+0.36 (1.55%)
At close: Jul 16, 2025, 4:00 PM
23.20
-0.36 (-1.53%)
After-hours: Jul 16, 2025, 7:37 PM EDT
Vera Therapeutics Employees
Vera Therapeutics had 112 employees as of December 31, 2024. The number of employees increased by 61 or 119.61% compared to the previous year.
Employees
112
Change (1Y)
61
Growth (1Y)
119.61%
Revenue / Employee
n/a
Profits / Employee
-$1,566,598
Market Cap
1.50B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 112 | 61 | 119.61% |
| Dec 31, 2023 | 51 | 5 | 10.87% |
| Dec 31, 2022 | 46 | 29 | 170.59% |
| Dec 31, 2021 | 17 | 9 | 112.50% |
| Dec 31, 2020 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VERA News
- 6 days ago - Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans - GlobeNewsWire
- 6 weeks ago - Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data - Benzinga
- 6 weeks ago - Vera shares skyrocket as kidney disease drug succeeds in late-stage trial - Reuters
- 6 weeks ago - Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy - GlobeNewsWire
- 2 months ago - Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug - Seeking Alpha
- 2 months ago - Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire